Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility
P Celichowski, M Turi, S Charvátová… - Journal of Translational …, 2023 - Springer
Cancer immunotherapies utilizing genetically engineered T cells have emerged as powerful
personalized therapeutic agents showing dramatic preclinical and clinical results …
personalized therapeutic agents showing dramatic preclinical and clinical results …
Are we ready for personalized CAR‐T therapy?
A Strzelec, G Helbig - European Journal of Haematology, 2024 - Wiley Online Library
The future of chimeric antigen receptor T (CAR‐T) therapy remains unclear. New studies are
constantly being published confirming the efficacy and favorable safety profile of its …
constantly being published confirming the efficacy and favorable safety profile of its …
Bibliometric analysis of research trends and active research areas in chimeric antigen receptor T cell therapy for hematologic malignancies
G Zhang, L Deng, H Lu, W Zhang - International Journal of Clinical …, 2024 - Springer
Background In the past decade, chimeric antigen receptor (CAR) T-cells have successfully
treated cancers, especially hematologic malignancies. Although many articles have been …
treated cancers, especially hematologic malignancies. Although many articles have been …
[HTML][HTML] How I treat newly diagnosed acute lymphoblastic leukemia
G Sebastian - Clinical Hematology International, 2024 - ncbi.nlm.nih.gov
Abstract Treatment algorithms differ for adult patients with Philadelphia-negative (Ph-) and
Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL). For Ph-ALL intensive …
Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL). For Ph-ALL intensive …